do insurance companies cover glp-1 drugs Why payers are hesitant to for weight loss Some insurers are dropping GLP-1

This single case does not establish causation, but it raises a flag that clinicians should be aware of, particularly in patients with pre-existing SLE or lupus-like features

Stimulation of release of insulin by an extract of intestinal mucosa

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Diabetes Metab Syndr Clin Res Rev

Liraglutide results in two placebo-controlled studies were similar with a systolic BP change of 5.6 mmHg (95% CI 5.8, 5.4) and diastolic BP change of 4.5 mmHg (95% CI 4.7, 4.3)

The benefits of these medications for body weight and diabetes management are well-established